Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Accumulating evidences suggest that killer cell immunoglobulin-like receptors (KIRs) contribute to the pathogenesis of diverse kinds of diseases. However, the functions and effects of KIR gene polymorphisms in the development of diseases remain largely unknown, especially about the activating KIR genes. To investigate the association of KIR gene polymorphisms with subtypes of leukemia, we carried out the present study on 263 patients with leukemia and 239 healthy controls by means of polymerase chain reaction-sequence-specific primer and analysis, and then all data were analyzed by Logistic regression method. Our results showed that the frame genotypes of KIR2DL4, 3DL2, 3DL3 and 3DP1 were expressed in all patients and all controls. The genotypes of KIR2DL1, 2DL3, 3DL1, and 2DP1 were most prevalent genotypes whose rates were more than 95% in all patients and all controls. The rate of activating KIR2DS4 was much higher in patients with CML than that in healthy controls (P<0.001) while the activating KIR2DS3 was lower in patients with ALL compared with healthy controls (P<0.05). There was no significant change of KIR genes found in patients with NALL. In conclusion, this study suggests that the activating KIR2DS4 may serve as CML susceptive gene to trigger leukemia development, while KIR2DS3 is possibly a protect gene of ALL.
 ...
PMID:Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease. 2188 24

The effect of natural killer (NK) cell alloreactivity on the outcome of unrelated hematopoietic SCT (HSCT) remains a topic of debate. NK cell alloreactivity after allogeneic HSCT is regulated by killer-cell Ig-like receptors (KIRs). To investigate the influence of KIRs on outcome after unrelated HSCT, we retrospectively analyzed the HLA and KIR genotypes of 116 donor-recipient pairs. We found that missing KIR ligands in recipients were significantly associated with a decreased leukemic relapse risk (P=0.019, HR=0.329), mainly in myeloid disease (P=0.003, HR=0.193). This beneficial effect was seen in AML/myelodysplastic syndrome and also in chronic myeloid leukemia. In myeloid disease, missing KIR ligands also improved 5-year OS (P=0.034, HR=0.430) and disease-free survival (DFS) (P=0.024, HR=0.445). Meanwhile, the presence of donor-activating KIR2DS3 gene was associated with increased relapse risk (P=0.003, HR=5.046), decreased OS (P=0.004, HR=3.181) and DFS (P=0.003, HR=2.919) in myeloid disease. No effect was seen in patients with lymphoid disease. Our study indicated that, in unrelated HSCT for myeloid leukemia, missing KIR ligands in recipients offered a lower relapse risk and a long-term survival advantage. The presence of KIR2DS3 in the donor was an important risk factor for myeloid leukemia.
 ...
PMID:The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. 2017 84